JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Current Understanding, Clinical Manifestations, and Therapeutic Approaches of Anxiety Disorders

Naveen V*[1], Felic S[1], Aswin AV[1], Arul Pakasam KC[2]

[1]*PharmD Intern, JKKMMRF'S Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India*
[2]*Professor and HOD, Department of Pharmacy Practice, JKKMMRF'S Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India*

Publication history: Received on 19th Aug; Revised on 29th Aug; Accepted on 2nd September 2024

Article DOI: 10.69613/xy1yek24

Abstract: Anxiety disorders represent a significant global mental health challenge, affecting approximately 4% of the world's population with a notably higher prevalence among women. These disorders encompass various conditions, including Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder, Specific Phobias, and Post-Traumatic Stress Disorder (PTSD). Each condition presents unique manifestations while sharing common features of excessive fear and worry that significantly impair daily functioning. The pathophysiology involves complex interactions between neurobiological systems, particularly the GABA, serotonin, and norepinephrine pathways, along with structural and functional changes in key brain regions such as the amygdala and prefrontal cortex. Recent advances in understanding genetic and epigenetic factors have revealed the role of genes like SLC6A4 and BDNF in anxiety susceptibility. Current treatment approaches combine psychological interventions, primarily Cognitive Behavioral Therapy (CBT), with pharmacological treatments such as Selective Serotonin Reuptake Inhibitors (SSRIs). Emerging therapeutic options, including ketamine therapy and Transcranial Magnetic Stimulation (TMS), show promise for treatment-resistant cases. Despite available treatments, barriers such as social stigma and limited access to mental health services prevent many individuals from seeking help. The aim of this review is to provide current knowledge about anxiety disorders.

Keywords: Anxiety disorders; Neurobiology of anxiety; Cognitive Behavioral Therapy; Pharmacotherapy; Mental health.

1. Introduction

Anxiety disorders represent one of the most prevalent categories of mental health conditions worldwide, significantly impacting individuals across all demographic groups and cultural boundaries. These disorders affect approximately 4% of the global population, with a markedly higher prevalence among women compared to men [1]. The economic burden associated with anxiety disorders is substantial, encompassing both direct healthcare costs and indirect expenses related to decreased productivity and quality of life [2]. The spectrum of anxiety disorders includes several distinct but interrelated conditions, each characterized by excessive and persistent fear or worry that extends beyond normal stress responses. These conditions include Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder, Specific Phobias, and Post-Traumatic Stress Disorder (PTSD) [3]. While each disorder presents unique features, they share common underlying mechanisms of heightened anxiety and psychological distress that significantly interfere with daily functioning.

The manifestation of anxiety disorders occurs through a complex interplay of psychological and physiological symptoms. Psychological manifestations typically include persistent feelings of apprehension, difficulty concentrating, and overwhelming worry, while physiological symptoms encompass cardiovascular, respiratory, and musculoskeletal responses [4]. This mind-body connection in anxiety disorders highlights the importance of understanding both the psychological and physiological aspects of these conditions for effective treatment [5]. Recent advances in neuroscience have enhanced our understanding of the neurobiological basis of anxiety disorders. Research has identified key neural circuits, particularly involving the amygdala, prefrontal cortex, and hippocampus, that play crucial roles in fear processing and anxiety regulation [6]. Additionally, studies have revealed the involvement of multiple neurotransmitter systems, including GABA, serotonin, and norepinephrine, providing targets for pharmacological interventions [7].

* Corresponding author: Naveen V

The development of anxiety disorders often involves a complex interaction between genetic predisposition and environmental factors. Twin studies have demonstrated substantial heritability for anxiety disorders, while environmental factors such as traumatic experiences, chronic stress, and early life adversity can significantly influence their onset and progression [8]. This understanding has led to the development of more targeted and personalized treatment approaches. Despite the availability of effective treatments, including both psychotherapeutic and pharmacological interventions, a significant treatment gap persists globally. Many individuals suffering from anxiety disorders do not receive appropriate care due to various barriers, including stigma surrounding mental health, limited access to mental health services, and insufficient awareness about the treatability of these conditions [9]. The COVID-19 pandemic has further exacerbated these challenges while simultaneously increasing the prevalence of anxiety symptoms worldwide [10]. The field of anxiety disorder treatment continues to evolve, with emerging therapeutic approaches showing promising results. Traditional treatments such as Cognitive Behavioral Therapy (CBT) and Selective Serotonin Reuptake Inhibitors (SSRIs) remain cornerstone interventions, while newer modalities including ketamine therapy, digital therapeutics, and neuromodulation techniques are expanding the treatment arsenal [11], [12]. The integration of these various approaches, along with increased emphasis on preventive strategies and early intervention, represents a crucial direction for improving outcomes in anxiety disorder management.

The aim of this review is to provide the current knowledge about anxiety disorders, including their classification, pathophysiology, clinical manifestations, and treatment approaches.

2. Clinical manifestations and diagnostic criteria

The clinical presentation of anxiety disorders encompasses a broad spectrum of psychological and somatic manifestations that significantly impact daily functioning. The psychological manifestations typically include persistent and excessive worry, heightened alertness to potential threats, and difficulty controlling anxious thoughts. These symptoms often create a cycle of anticipatory anxiety, where individuals experience distress about future events or situations, leading to maladaptive avoidance behaviors [13]. Somatic manifestations of anxiety disorders frequently involve multiple organ systems. Cardiovascular symptoms include palpitations, chest tightness, and increased blood pressure, while respiratory symptoms manifest as shortness of breath and hyperventilation. Gastrointestinal disturbances commonly present as nausea, appetite changes, and digestive issues. Musculoskeletal symptoms often include muscle tension, tremors, and fatigue [14]. The diagnostic process for anxiety disorders requires careful consideration of symptom duration, severity, and impact on functioning. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), anxiety symptoms must persist for at least six months and cause significant distress or impairment in social, occupational, or other important areas of functioning to warrant a diagnosis [15]. The assessment process typically involves comprehensive clinical interviews, standardized diagnostic tools, and careful exclusion of other medical conditions that may present with similar symptoms [16].

3. Classification of anxiety disorders

Anxiety disorders comprise several distinct conditions, each with unique characteristics and diagnostic criteria (Table 1). Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about various aspects of life, accompanied by physical symptoms such as restlessness, fatigue, and sleep disturbances. GAD typically follows a chronic course, with symptoms fluctuating in severity over time [17].

Social Anxiety Disorder (SAD) manifests as intense fear of social situations and scrutiny by others. Individuals with SAD experience significant distress in social interactions, often leading to avoidance behaviors that can severely limit educational, occupational, and social opportunities. The fear of negative evaluation and embarrassment is disproportionate to the actual threat posed by social situations [18].

Panic Disorder is characterized by recurrent, unexpected panic attacks, accompanied by persistent concern about future attacks or their implications. These attacks involve intense physical symptoms such as accelerated heart rate, sweating, trembling, and a sense of impending doom. The unpredictable nature of panic attacks often leads to anticipatory anxiety and agoraphobic avoidance [19].

Specific Phobias involve marked fear or anxiety about particular objects or situations, such as heights, animals, or blood. The fear response is immediate and intense, leading to active avoidance of the phobic stimulus. While individuals with specific phobias often recognize their fear as excessive, they remain unable to control their response when confronted with the feared situation [20]

Table 1. Classification of anxiety disorders and their characteristic symptoms

Anxiety Disorder	Core Symptoms	DSM-5 Diagnostic Criteria	DSM-5 Code
Generalized Anxiety Disorder (GAD)	Excessive worry, restlessness, fatigue, difficulty concentrating, irritability, muscle tension, sleep disturbance	Worry about various events or activities occurring more days than not for at least 6 months. Physical symptoms and difficulty controlling worry. Causes significant distress.	300.02
Panic Disorder	Recurrent unexpected panic attacks, palpitations, sweating, trembling, feelings of choking, fear of dying	Recurrent panic attacks, followed by one month of concern about future attacks or maladaptive behavior changes to avoid them. Symptoms cannot be attributed to substances or medical conditions.	300.01
Social Anxiety Disorder (Social Phobia)	Intense fear of social situations, avoidance, anxiety out of proportion to the situation, fear of embarrassment or humiliation	Persistent fear or anxiety about social situations where scrutiny is possible, lasting at least 6 months. The fear causes avoidance or extreme distress and affects daily functioning.	300.23
Specific Phobia	Marked fear or anxiety about a specific object or situation, avoidance behavior, panic attacks	Intense fear of a specific object or situation, leading to avoidance. The fear is out of proportion to actual danger and persists for 6 months or more. Interferes with daily functioning.	300.29
Agoraphobia	Fear of being in situations where escape might be difficult, avoidance of open or crowded places	Fear of two or more situations such as using public transportation, being in open spaces, or standing in line. Fear or avoidance behavior lasts for at least 6 months.	300.22
Obsessive-Compulsive Disorder (OCD)	Recurrent obsessions (thoughts) or compulsions (behaviors), distressing, time-consuming	Presence of obsessions (recurrent intrusive thoughts) or compulsions (repetitive behaviors) aimed at reducing distress, taking more than one hour per day and causing significant impairment.	300.3
Post-Traumatic Stress Disorder (PTSD)	Intrusive memories, nightmares, hypervigilance, flashbacks, avoidance of trauma-related cues	Exposure to a traumatic event, with symptoms persisting for more than one month. Includes re-experiencing the trauma, avoidance, negative mood changes, and hyperarousal symptoms.	309.81

4. Pathophysiological mechanisms

The pathophysiology of anxiety disorders involves intricate interactions between neural circuits, neurotransmitter systems, and neuroendocrine pathways. The neurobiological basis centers on the dysregulation of key brain regions involved in fear processing and emotional regulation (Table 2). The amygdala, often considered the fear center of the brain, typically shows hyperactivation in individuals with anxiety disorders, leading to heightened threat detection and emotional reactivity [21]. This hyperactivation is accompanied by reduced functional connectivity between the amygdala and the prefrontal cortex, compromising emotional regulation capabilities [22].

The neurotransmitter systems implicated in anxiety disorders demonstrate complex alterations. The gamma-aminobutyric acid (GABA) system, the primary inhibitory neurotransmitter network, often shows reduced functionality in anxiety disorders. This reduction in GABA signaling results in decreased neural inhibition and increased excitability in anxiety-related neural circuits [23]. The serotonergic system plays a crucial role in mood regulation and anxiety modulation, with alterations in serotonin receptor density and function contributing to anxiety symptoms. This understanding has led to the development of selective serotonin reuptake inhibitors (SSRIs) as primary pharmacological interventions [24].

The noradrenergic system, particularly the locus coeruleus, demonstrates hyperactivity in anxiety disorders, contributing to increased arousal and vigilance. This hyperactivity results in enhanced sympathetic nervous system responses, manifesting as physical symptoms such as increased heart rate and sweating [25]. The hypothalamic-pituitary-adrenal (HPA) axis, central to stress response

regulation, often shows dysregulation in anxiety disorders. This leads to abnormal cortisol secretion patterns and altered stress reactivity, creating a perpetual state of physiological arousal [26].

Neuroplastic changes in anxiety-related neural circuits have been observed through neuroimaging studies. These changes include alterations in gray matter volume in regions such as the hippocampus and anterior cingulate cortex, which are crucial for contextual learning and emotional processing [27]. Additionally, white matter tract abnormalities have been identified, suggesting compromised neural connectivity in anxiety-related networks [28]

Table 2. Neurotransmitter Systems Involved in Anxiety Disorders

Neurotransmitter	Role in Normal Function	Alterations in Anxiety Disorders
GABA	Primary inhibitory transmitter; Reduces neuronal excitability	Reduced activity; decreased binding; Impaired inhibitory control
Serotonin (5-HT)	Mood regulation; Anxiety modulation	Altered receptor sensitivity; Dysregulated serotonergic transmission
Norepinephrine	Arousal and vigilance; Stress response	Hyperactive noradrenergic system; Enhanced sympathetic activity
Glutamate	Learning and memory; Synaptic plasticity	Excessive excitatory neurotransmission; Altered glutamate receptor function
Dopamine	Reward and motivation; Fear learning	Disrupted reward processing; Altered fear conditioning
CRH/HPA axis	Stress response coordination; Adaptive behavior	Hyperactive stress response; Impaired negative feedback

5. Risk factors and biology

The development of anxiety disorders involves a complex interplay of genetic, environmental, and psychological factors. Genetic studies have revealed a strong hereditary component, with twin studies suggesting heritability rates ranging from 30-50% depending on the specific anxiety disorder [29]. Several candidate genes have been identified, including those involved in serotonin transport (SLC6A4), neurotrophic factors (BDNF), and stress response regulation (FKBP5). These genetic variations can influence individual susceptibility to anxiety disorders through alterations in neurotransmitter function and stress response systems [30]. Environmental factors play a crucial role in the manifestation of anxiety disorders. Early life experiences, particularly childhood trauma, abuse, or neglect, significantly increase the risk of developing anxiety disorders in adulthood [31]. Parenting styles characterized by overprotection or excessive control can contribute to the development of anxiety by limiting a child's opportunities to develop effective coping mechanisms and autonomy. Additionally, societal factors such as socioeconomic status, educational level, and cultural background influence both the prevalence and presentation of anxiety disorders [32].

The interaction between genetic predisposition and environmental factors occurs through epigenetic mechanisms, which can modify gene expression without altering the DNA sequence. Stressful life experiences can lead to epigenetic changes that affect the regulation of genes involved in stress response and emotional processing [33]. These modifications can persist over time and even be transmitted across generations, contributing to the intergenerational transmission of anxiety vulnerability [34].

Psychological factors, including cognitive biases and learned responses, contribute significantly to the development and maintenance of anxiety disorders. Individuals with anxiety disorders often demonstrate attention bias toward threat, interpretation bias favoring negative outcomes, and memory bias for anxiety-provoking information [35]. These cognitive patterns can be established early in life and reinforced through avoidance behaviors and negative experiences. Furthermore, maladaptive coping strategies and belief systems about threat and control can perpetuate anxiety symptoms [36]. Neurobiological development during critical periods, particularly adolescence, can influence vulnerability to anxiety disorders. During these periods, brain regions involved in emotion regulation and fear processing undergo significant maturation. Disruption of this development through stress or trauma can lead to lasting alterations in neural circuits relevant to anxiety [37]. Understanding these developmental trajectories is crucial for identifying opportunities for early intervention and prevention [38].



Figure 1. Pathophysiology of Anxiety

6. Current therapeutic approaches

The management of anxiety disorders typically employs a multimodal approach, combining psychological interventions with pharmacological treatments (Table 3). Cognitive Behavioral Therapy (CBT) remains the gold standard psychological intervention, demonstrating robust efficacy across various anxiety disorders. CBT encompasses multiple therapeutic components, including cognitive restructuring, exposure therapy, and relaxation techniques. The therapy helps patients identify and challenge maladaptive thought patterns while developing more effective coping strategies [39]. Recent adaptations of CBT, including mindfulness-based cognitive therapy (MBCT), have shown promising results in reducing anxiety symptoms and preventing relapse [40].

Table 3. Evidence-Based Treatment Options for Anxiety Disorders

Treatment Modality	Primary Indications	Effectiveness	Onset of Action	Side Effects/Limitations
SSRIs (First-line)	All anxiety disorders	High (60-70% response rate)	4-6 weeks	Initial anxiety, sexual dysfunction, GI disturbance
CBT (First-line)	All anxiety disorders	High (50-75% response rate)	8-12 weeks	Time-intensive, requires patient engagement
SNRIs	GAD, Social Anxiety, Panic Disorder	Moderate to High (55-65% response rate)	4-6 weeks	Hypertension, withdrawal symptoms
Benzodiazepines	Acute anxiety, Panic attacks	Very High (70-80% response rate)	Immediate	Dependence risk, cognitive impairment
MBCT	GAD, Social Anxiety, Relapse prevention	Moderate (45-60% response rate)	8-10 weeks	Requires regular practice
Digital CBT interventions	Mild to moderate anxiety	Moderate (40-55% response rate)	6-12 weeks	Limited personal interaction

Pharmacological interventions primarily target the neurochemical imbalances associated with anxiety disorders. Selective Serotonin Reuptake Inhibitors (SSRIs) serve as first-line medications, with agents such as sertraline, escitalopram, and fluoxetine showing consistent efficacy. These medications work by increasing serotonin availability in the synaptic cleft, thereby modulating mood and anxiety responses [41]. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine and duloxetine provide an alternative first-line option, particularly effective in cases with comorbid depression [42]. Other pharmacological options include benzodiazepines, which are prescribed for acute anxiety management but require careful monitoring due to their potential for dependence and cognitive side effects. Buspirone, a partial serotonin receptor agonist, offers an alternative for GAD treatment with

a lower risk profile. Beta-blockers may be prescribed for specific situations, particularly in performance anxiety, to manage physical symptoms [43]. The selection of appropriate medication requires careful consideration of individual factors, including comorbid conditions, side effect profiles, and patient preferences [44].



Figure 2. Effectiveness of various treatment approaches

7. Emerging Treatment modalities

Recent advances in neuroscience and technology have led to innovative therapeutic approaches for anxiety disorders. Ketamine therapy has emerged as a promising intervention for treatment-resistant cases, with rapid-acting anxiolytic effects observed in clinical trials. The mechanism involves modulation of glutamate neurotransmission and enhancement of synaptic plasticity, potentially leading to rapid symptom improvement [45]. Psychedelic-assisted therapy, particularly with psilocybin and MDMA, is under investigation for anxiety disorders, showing preliminary promise in combination with psychotherapy [46].

Neuromodulation techniques represent another frontier in anxiety treatment. Transcranial Magnetic Stimulation (TMS) targets specific brain regions involved in anxiety circuits, with evidence supporting its efficacy in reducing symptoms. Deep Brain Stimulation (DBS), while more invasive, has shown potential for severe, treatment-resistant cases by directly modulating dysfunctional neural circuits [47]. Vagus Nerve Stimulation (VNS) offers a less invasive neuromodulation approach, influencing anxiety-related neural pathways through peripheral nerve stimulation [48]. Digital therapeutics and technology-based interventions have gained prominence, particularly following the COVID-19 pandemic. Virtual reality exposure therapy (VRET) provides controlled environments for exposure treatment, especially beneficial for specific phobias and social anxiety. Mobile applications delivering CBT-based interventions have shown effectiveness in increasing treatment accessibility and maintaining therapeutic gains [49]. Artificial intelligence-driven platforms offer personalized treatment recommendations and progress monitoring, enhancing treatment optimization [50].

8. Prevention and early intervention

Prevention strategies focus on identifying and addressing risk factors before the full development of anxiety disorders. Primary prevention programs target vulnerable populations, particularly children and adolescents, through school-based interventions that enhance emotional resilience and coping skills [51]. These programs incorporate elements of social-emotional learning, stress management, and problem-solving skills, proving effective in reducing the incidence of anxiety disorders [52]. Early intervention initiatives emphasize the identification of prodromal symptoms and subclinical anxiety. Screening programs in primary care settings, schools, and community centers facilitate early detection and referral to appropriate services. Brief interventions delivered during this critical period can prevent the progression to full-blown anxiety disorders and reduce the likelihood of chronic impairment [53]. Parent-focused interventions that address family dynamics and parenting styles have shown particular promise in preventing anxiety disorders in children [54].

The development of resilience-building strategies plays a crucial role in prevention. These approaches include mindfulness training, regular physical exercise, and stress management techniques. Workplace wellness programs incorporating these elements have demonstrated effectiveness in reducing anxiety symptoms and improving overall mental health outcomes [55]. Community-based initiatives that address social determinants of mental health, including poverty, discrimination, and social isolation, contribute to comprehensive prevention strategies [56]. Digital platforms and telemedicine services have expanded the reach of preventive interventions, enabling early identification and intervention in previously underserved populations. Online screening tools, self-help

resources, and guided intervention programs provide accessible support for individuals at risk of developing anxiety disorders [57]. Integration of these digital solutions with traditional healthcare services creates comprehensive prevention networks capable of reaching diverse populations [58, 59].

9. Conclusion

Anxiety disorders represent a significant global health challenge that requires continued attention from healthcare providers, researchers, and policymakers. The complex interplay of biological, psychological, and environmental factors in these disorders necessitates a comprehensive approach to both treatment and prevention. While established interventions like CBT and pharmacotherapy remain fundamental, emerging therapeutic modalities and digital solutions offer promising avenues for improving treatment outcomes. The integration of early intervention strategies, coupled with efforts to reduce stigma and increase access to mental health services, is crucial for addressing the growing burden of anxiety disorders.

References

[1] Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327-35.

[2] Chisholm D, Sweeny K, Sheehan P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry. 2016;3(5):415-24.

[3] Craske MG, Stein MB. Anxiety. Lancet. 2016;388(10063):3048-59.

[4] Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues Clin Neurosci. 2002;4(3):231-49.

[5] McEwen BS. Neurobiological and systemic effects of chronic stress. Chronic Stress. 2017;1:2470547017692328.

[6] Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015;16(6):317-31.

[7] Goddard AW. The neurobiology of panic: a chronic stress disorder. Chronic Stress. 2017;1:2470547017736038.

[8] Asogwa PO, Sarella PN. Observational Studies of Prescription Pattern and Use of Antibiotics in Selected Rural Areas. Int J Pharm Sci and Medicine. 2023;8:21-30.

[9] Alonso J, Liu Z, Evans-Lacko S, et al. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018;35(3):195-208.

[10] Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;277:55-64.

[11] Krystal JH, Davis LL, Neylan TC, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82(7):e51-e59.

[12] WHO. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017.

[13] Barlow DH, Durand VM. Abnormal psychology: An integrative approach. 8th ed. Boston: Cengage Learning; 2018.

[14] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

[15] Stein DJ, Scott KM, de Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017;19(2):127-36.

[16] Sarella PN, Mangam VT. AI-Driven Natural Language Processing in Healthcare: Transforming Patient-Provider Communication. Indian Journal of Pharmacy Practice. 2024;17(1).

[17] Maron E, Nutt D. Biological markers of generalized anxiety disorder. Dialogues Clin Neurosci. 2017;19(2):147-58.

[18] Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115-25.

[19] Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006;368(9540):1023-32.

[20] Wardenaar KJ, Lim CCW, Al-Hamzawi AO, et al. The cross-national epidemiology of specific phobia in the World Mental Health Surveys. Psychol Med. 2017;47(10):1744-60.

[21] Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010;35(1):169-91.

[22] Sarella PN, Dadishetti JP, Asogwa PO, Kakarparthy R. Pharmacological and Non-pharmacological Management of Bipolar Disorder with Comorbid Huntington's Disease: A Case Report. Journal of Clinical and Pharmaceutical Research. 2023 Apr 30:5-8.

[23] Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat. 2015;11:165-75.

[24] Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-39.

[25] Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry. 1999;46(9):1219-33.

[26] Faravelli C, Lo Sauro C, Lelli L, et al. The role of life events and HPA axis in anxiety disorders: a review. Curr Pharm Des. 2012;18(35):5663-74.

[27] Kim MJ, Loucks RA, Palmer AL, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res. 2011;223(2):403-10.

[28] Baur V, Hänggi J, Langer N, Jäncke L. Resting-state functional and structural connectivity within an insula-amygdala route specifically index state and trait anxiety. Biol Psychiatry. 2013;73(1):85-92.

[29] Smoller JW. The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology. 2016;41(1):297-319.

[30] Sharma S, Powers A, Bradley B, Ressler KJ. Gene × Environment Determinants of Stress- and Anxiety-Related Disorders. Annu Rev Psychol. 2016;67:239-61.

[31] McLaughlin KA, Green JG, Gruber MJ, et al. Childhood adversities and adult psychiatric disorders in the National Comorbidity Survey Replication II. Arch Gen Psychiatry. 2010;67(2):124-32.

[32] Kessler RC, McLaughlin KA, Green JG, et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry. 2010;197(5):378-85.

[33] Klengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene × Environment Interactions. Neuron. 2015;86(6):1343-57.

[34] Yehuda R, Lehrner A. Intergenerational transmission of trauma effects: putative role of epigenetic mechanisms. World Psychiatry. 2018;17(3):243-57.

[35] Sarella PN, Valluri S, Vegi S, Vendi VK, Vipparthi AK. Microneedle Arrays: Advancements, Applications and Future Prospects in Pharmaceutical Delivery. Asian Journal of Pharmacy and Technology. 2024 Sep 19;14(3):229-36.

[36] Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis. 2007;195(6):521-31.

[37] Gabard-Durnam LJ, McLaughlin KA. Do sensitive periods exist for exposure to adversity? Biol Psychiatry. 2019;85(10):789-91.

[38] Pine DS, Fox NA. Childhood antecedents and risk for adult mental disorders. Annu Rev Psychol. 2015;66:459-85

[39] Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69(4):621-32.

[40] Khoury B, Lecomte T, Fortin G, et al. Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev. 2013;33(6):763-71.

[41] Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84.

[42] Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772-85.

[43] Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009;70 Suppl 2:25-31.

[44] Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768-77.

[45] Krystal JH, Davis LL, Neylan TC, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82(7):e51-e59.

[46] Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3(5):481-88.

[47] Bystritsky A, Kerwin LE, Feusner JD. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. J Clin Psychiatry. 2008;69(3):412-17.

[48] George MS, Ward HE Jr, Ninan PT, et al. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008;1(2):112-21.

[49] Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. J Anxiety Disord. 2018;55:70-78.

[50] Twomey C, O'Reilly G, Meyer B. Effectiveness of an individually-tailored computerised CBT programme for anxiety and depression. Br J Clin Psychol. 2017;56(1):1-16.

[51] Werner-Seidler A, Perry Y, Calear AL, et al. School-based depression and anxiety prevention programs for young people: A systematic review and meta-analysis. Clin Psychol Rev. 2017;51:30-47.

[52] Stockings EA, Degenhardt L, Dobbins T, et al. Preventing depression and anxiety in young people: a review of the joint efficacy of universal, selective and indicated prevention. Psychol Med. 2016;46(1):11-26.

[53] Batelaan NM, Smit F, de Graaf R, et al. Economic costs of anxiety disorders: a population-based study. J Affect Disord. 2007;104(1-3):437-46.

[54] Rapee RM, Kennedy S, Ingram M, et al. Prevention and early intervention of anxiety disorders in inhibited preschool children. J Consult Clin Psychol. 2005;73(3):488-97.

[55] Joyce S, Modini M, Christensen H, et al. Workplace interventions for common mental disorders: a systematic meta-review. Psychol Med. 2016;46(4):683-97.

[56] Allen J, Balfour R, Bell R, Marmot M. Social determinants of mental health. Int Rev Psychiatry. 2014;26(4):392-407.

[57] Andersson G, Titov N. Advantages and limitations of Internet-based interventions for common mental disorders. World Psychiatry. 2014;13(1):4-11.

[58] Riper H, Andersson G, Christensen H, et al. Theme issue on e-mental health: a growing field in internet research. J Med Internet Res. 2010;12(5):e74.

[59] Holmes EA, Ghaderi A, Harmer CJ, et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. Lancet Psychiatry. 2018;5(3):237-86